Hasan et al. analyzed a total of 13 randomized controlled clinical trials including 75,287 patients demonstrating that SGLT-2 inhibitors significantly reduce the risk of hospitalization in patients with HF irrespective of their diabetes status but showed a significant reduction in mortality risk only in diabetics (Relative Risk (RR) =0.87,95% Confidence Interval (CI): 0.77-0.99) [7]. This evidence concerns the gene SLC5A2 and diabetes mellitus.